Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy

被引：0
|
作者：
Song, Zhengbo [1 ]
Zhang, Yiping [2 ]
Yuz, Xinmin [1 ]
机构：
[1] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Thymidylate synthetase; ros1; pemetrexed; efficacy;
D O I：
10.1016/j.jtho.2016.11.1659
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02a-029
引用
收藏
页码：S1179 / S1180
页数：2
相关论文
共 50 条
  • [31] Chemotherapy-induced leukopenia as a prognostic factor in patients with metastatic non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Aimi
    Ma, Meili
    Jin, Bo
    Han, Baohui
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (02): : 5241 - 5248
  • [32] Re-administration of Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Who Recovered from Chemotherapy-induced Interstitial Lung Disease
    Kashiwabara, Kosuke
    Semba, Hiroshi
    Fujii, Shinji
    Tsumura, Shinsuke
    IN VIVO, 2018, 32 (04): : 851 - 857
  • [33] Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre
    Panda, Goutam Santosh
    Noronha, Vanita
    Patil, Vijay
    Joshi, Amit
    Menon, Nandini
    Kumar, Rajiv
    Pai, Trupti
    Shetty, Omshree
    Janu, Amit
    Chakrabarty, Nivedita
    Purandare, Nilendu
    Dey, Sayak
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2024, 18
  • [34] Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis
    Qi, Wei-Xiang
    Tang, Li-Na
    He, Ai-Na
    Shen, Zan
    Yao, Yang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (05) : 745 - 751
  • [35] Pooled analysis of the clinical benefit of cyclooxygenase-2 inhibitors combined with chemotherapy in advanced non-small cell lung cancer
    Zheng, Wei
    Liao, Zhi-Min
    Fu, Yan
    Wu, Ya-Peng
    Zhang, Qiong
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (04) : 1258 - 1267
  • [36] Erlotinib versus chemotherapy (docetaxel/pemetrexed) as second-line therapy in advanced non-small cell lung cancer: a meta-analysis
    Li, Yong
    Cheng, Ting
    Chen, Ling
    Cheng, Qijian
    Wan, Huanying
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (03): : 4606 - 4617
  • [37] Response to First-Line Chemotherapy in Patients with Non-Small Cell Lung Cancer According to RRM1 Expression
    Dong, Xiaopeng
    Hao, Yingtao
    Wei, Yucheng
    Yin, Qiuwei
    Du, Jiajun
    Zhao, Xiaogang
    PLOS ONE, 2014, 9 (03):
  • [38] Serum ferritin is elevated in advanced non-small cell lung cancer patients and is associated with efficacy of platinum-based chemotherapy
    Shi, Hong-Bing
    Li, Xiao-Dong
    Jiang, Jing-Ting
    Zhao, Wei-Qing
    Ji, Mei
    Wu, Chang-Ping
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2014, 10 (03) : 681 - 685
  • [39] Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer
    Okamoto, Isamu
    Takeda, Koji
    Daga, Haruko
    Miyazaki, Masaki
    Yonesaka, Kimio
    Kiyota, Hidemi
    Tsurutani, Junji
    Ueda, Shinya
    Ichikawa, Yasuko
    Takeda, Masayuki
    Sekiguchi, Risa
    Tominaga, Kiyomi
    Enatsu, Sotaro
    Nambu, Yoshihiro
    Nakagawa, Kazuhiko
    LUNG CANCER, 2010, 70 (02) : 168 - 173
  • [40] A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
    Dong, Shuang
    Ou, Wuling
    Zhong, Yi
    Zhu, Xianmin
    Cai, Qian
    Zhang, Jing
    Ran, Fengming
    Qian, Yu
    Wang, Jun
    Hu, Sheng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (02)
12345